Reata Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Reata Pharmaceuticals generated cash of -$204,267,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,485,000 last year. Net change in cash is therefore -$547,946,000.
Cash Flow
| 2013 | -68.94M | 2.15M | 1.65M |
|---|---|---|---|
| 2014 | -88.63M | -140K | 1K |
| 2015 | -44.62M | -260K | -870K |
| 2016 | -19.25M | -339K | 62.32M |
| 2017 | -83.25M | -343K | 128.64M |
| 2018 | -83.78M | -679K | 292.47M |
| 2019 | -251.15M | -2.67M | 580.35M |
| 2020 | -322.34M | -927K | 477.09M |
| 2021 | -235.70M | -1.32M | 9.13M |
| 2022 | -204.26M | -345.16M | 1.48M |
RETA Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 590.25M | 818.15M | 664.32M | 337.79M | 129.78M | 84.73M | 42.00M | 87.75M | 176.52M | 241.67M |
Operating activities | ||||||||||
Net income | -311.90M | -297.38M | -247.75M | -290.17M | -80.54M | -47.67M | -6.22M | -1.45M | 689K | -35.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.13M | 1.20M | 1.13M | 932K | 431K | 437K | 682K | 1.81M | 2.51M | 2.92M |
Stock-based compensation expense | 58.73M | 56.80M | 57.63M | 26.38M | 10.55M | 6.53M | 2.36M | 2.07M | 1.52M | 2.36M |
| Deferred income tax benefit | 58.73M | 56.80M | 57.63M | 26.38M | 10.55M | 6.53M | 2.36M | 2.07M | 1.52M | 2.36M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 198K | -223K | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -603K | 2.35M | 0 |
Accounts payable | 5.20M | 8.71M | 2.87M | -2.11M | 1.95M | -1.76M | 299K | 2.75M | -1.65M | 182K |
Cash generated by operating activities | -204.26M | -235.70M | -322.34M | -251.15M | -83.78M | -83.25M | -19.25M | -44.62M | -88.63M | -68.94M |
Investing activities | ||||||||||
Purchases Of Investments | -661.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.27M | -1.32M | -927K | -2.67M | -679K | -344K | -340K | -272K | -183K | -325K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -345.16M | -1.32M | -927K | -2.67M | -679K | -343K | -339K | -260K | -140K | 2.15M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 333.27M | 333.27M | 492.45M | 233.49M | 108.91M | 64.70M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -460K |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -145K |
Repayments of term debt | 0 | 0 | -167.17M | 0 | 0 | 0 | -45K | 0 | 0 | 0 |
Cash used in financing activities | 1.48M | 9.13M | 477.09M | 580.35M | 292.47M | 128.64M | 62.32M | -870K | 1K | 1.65M |
Net Change In Cash | -547.94M | -227.89M | 153.82M | 326.53M | 208.01M | 45.04M | 42.72M | -45.75M | -88.76M | -65.14M |
Cash at end of period | 42.31M | 590.25M | 818.15M | 664.32M | 337.79M | 129.78M | 84.73M | 42.00M | 87.75M | 176.52M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |